AiTan (rivoceranib) / Jiangsu Hengrui Pharma, HLB Bio Group, Bukwang Pharma, Advenchen - LARVOL DELTA

Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial. (PubMed, Lancet) - P1/2 | "This is the first randomised controlled trial of CAR T-cell therapy in solid tumours globally. Satri-cel treatment resulted in a significant improvement in progression-free survival, with a manageable safety profile. These results support satri-cel as a new third-line treatment for advanced gastric or gastro-oesophageal junction cancer patients."

Journal • P2 data • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor • CLDN18

Perioperative camrelizumab plus rivoceranib in resectable hepatocellular carcinoma (CARES-009): A randomized, multicenter, phase III trial (ESMO 2025) - P2/3 | "Grade ≥3 treatment-related adverse events occurred in 37.6% of patients in the perioperative group. Conclusions Perioperative camrelizumab plus rivoceranib significantly improved EFS and MPR compared with surgery alone in patients with resectable HCC at intermediate or high-risk of recurrence."

Clinical • P3 data • Hepatocellular Cancer • Oncology • Solid Tumor

HLB advances China review of Rivoceranib combo as US resubmission proceeds (Chosun Biz) - "HLB said on the 2nd that its Chinese partner Jiangsu Hengrui Pharmaceuticals recently received a notice from China's National Medical Products Administration (NMPA) that it has begun the substantive review of the combination therapy of 'Rivoceranib, Camrelizumab, and transarterial chemoembolization (TACE)' for patients with unresectable hepatocellular carcinoma. The application is based on the results of a phase 3 clinical trial conducted with 423 patients at 34 medical institutions in China."

China filing • Hepatocellular Cancer

Camrelizumab plus apatinib in patients with advanced or refractory chordoma: A single-arm, open-label, phase 2 trial. (ASCO 2025) - P2 | "The combination of camrelizumab and apatinib demonstrated promising efficacy and manageable toxicity in chordoma treatment. Furthermore, CDKN2A alterations (CND or HD) were associated with poorer outcomes, providing a potential biomarker for therapeutic stratification."

Clinical • IO biomarker • Metastases • P2 data • Chordoma • CDKN2A

MA-GC-II-019: Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer (clinicaltrials.gov) - P2 | N=80 | Active, not recruiting | Sponsor: Ruijin Hospital | Not yet recruiting ➔ Active, not recruiting

Enrollment closed • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor

Neoadjuvant camrelizumab plus apatinib and temozolomide for resectable stage II/III acral melanoma: The CAP 03-NEO trial. (ASCO 2025) - P2 | "Stage 1 results of CAP 03-NEO demonstrated the potential of neoadjuvant camrelizumab, apatinib and temozolomide in pts with resectable stage II/III AM. The pNR result support advancing to stage 2 to further assess the efficacy and safety of this regimen in pts with stage III disease."

Clinical • Constipation • Gastroenterology • Gastrointestinal Disorder • Melanoma • Oncology • Solid Tumor

Elevar Therapeutics Announces FDA Acceptance of New Drug Application Resubmission for Rivoceranib in Combination with Camrelizumab as a First-line Systemic Treatment for Unresectable Hepatocellular Carcinoma (GlobeNewswire) - "The FDA assigned a Prescription Drug User Fee Act (PDUFA) target action date of July 23, 2026....Elevar on Jan. 23, 2026, submitted the NDA for rivoceranib, while Hengrui Pharma submitted a biologics license application (BLA) for camrelizumab....In Elevar’s global Phase 3 CARES-310 study, the camrelizumab plus rivoceranib combination therapy achieved a median overall survival of 23.8 months in patients with uHCC, representing the longest overall survival reported to date among first-line treatments for uHCC."

FDA filing • PDUFA • Hepatocellular Cancer

Exploratory phase II trial of camrelizumab (an anti-PD-1 antibody) combined with apatinib (a VEGFR-2 inhibitor) and chemotherapy as a neoadjuvant therapy for triple-negative breast cancer (NeoPanDa03): efficacy, safety and biomarker analysis (SABCS 2025) - P2 | "The treatment regimen consisted of camrelizumab (200 mg intravenously every 2 weeks, 12 cycles), apatinib (250 mg orally daily), and alternating chemotherapy [nab-paclitaxel (d1, 8, 15 every 4 weeks) for 4 cycles and epirubicin plus cyclophosphamide (every 2 weeks) for 4 cycles]. From June 2023 to April 2024, 35 patients were enrolled, of whom 1 patient withdrew due to adverse reaction intolerance. In conclusion, camrelizumab and apatinib combined with chemotherapy have good clinical efficacy and good safety as neoadjuvant treatments for stage II-III TNBC, warranting further investigation and potential clinical application. This innovative dual-score system stratifies pretreatment prognosis (PRPscore) and dynamically evaluates therapeutic efficacy (EAscore), enabling precision neoadjuvant optimization."

Biomarker • Clinical • IO biomarker • P2 data • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • CD4 • CXCL1 • IL17A • IL18 • MMP7 • PD-L1 • TP53

Neoadjuvant TACE Combined with Camrelizumab and Apatinib for Centrally Located Hepatocellular Carcinoma(NEO-CENTACT): A Single-Arm, Prospective, Exploratory Study (ChiCTR) - P=N/A | N=40 | Not yet recruiting | Sponsor: West China Hospital, Sichuan University; Sichuan University West China Hospital

New trial • Hepatocellular Cancer • Oncology • Solid Tumor

Camrelizumab plus Rivoceranib as first-line maintenance therapy after Camrelizumab-Chemo induction in advanced esophageal squamous cell carcinoma: a prospective, single-arm, phase II clinical trial (ChiCTR) - P2 | N=38 | Not yet recruiting | Sponsor: The First Affiliated Hospital of China Medical University; The First Affiliated Hospital of China Medical University

New P2 trial • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma

HLB said on the 26th that U.S. subsidiary Elevar Therapeutics (hereafter Elevar) and partner Jiangsu Hengrui Pharmaceuticals on the 23rd (local time) completed resubmitting a new drug application to the U.S. Food and Drug Administration (FDA) for a combination therapy of the targeted anticancer drug Rivoceranib and the immunotherapy Camrelizumab for liver cancer (Chosun Biz) - "Elevar submitted a new drug application (NDA) for Rivoceranib, a small-molecule vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI), and Jiangsu Hengrui Pharmaceuticals submitted a biologics license application (BLA) for Camrelizumab, an anti–PD-1 antibody. Because the two drugs were tested as a combination therapy, the FDA regards them as a single treatment and is conducting an integrated review."

FDA filing • Hepatocellular Cancer

ESIRA, a novel framework integrating efficacy and safety for evaluating first-line treatments in advanced hepatocellular carcinoma. (PubMed, Sci China Life Sci) - "Nivolumab plus ipilimumab ranked highest when the safety weight exceeded 0.7, whereas sintilimab plus bevacizumab and camrelizumab plus apatinib rose sharply in ranking when the efficacy weight exceeded 0.8. In addition, ESIRA rankings were reproduced in two independent validation cohorts, further demonstrating consistency across heterogeneous datasets. By quantitatively integrating multiple clinical outcomes, ESIRA provides a structured approach to treatment selection that may better capture the trade-offs encountered in real-world clinical decision-making for advanced HCC."

Journal • Hepatocellular Cancer • Oncology • Solid Tumor

Checkpoint Inhibition in Gestational Trophoblastic Neoplasia: A Narrative Review on the Reawakening of Antitumor Immunity. (PubMed, Adv Ther) - "Immunotherapy has expanded therapeutic GTN, transforming refractory disease as a result of its immune responsiveness. Checkpoint inhibition not only achieves high remission rates but also offers fertility preservation and long-term survivorship. The future challenge lies in optimizing combination strategies, refining biomarkers, and ensuring equitable global access to these emerging treatments."

Checkpoint inhibition • IO biomarker • Journal • Review • Gestational Trophoblastic Neoplasia • Oncology • KDR

DRAGON - IV: Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer (clinicaltrials.gov) - P2/3 | N=580 | Active, not recruiting | Sponsor: Ruijin Hospital | Trial completion date: Aug 2025 ➔ Dec 2027 | Trial primary completion date: Dec 2024 ➔ Dec 2026

Trial completion date • Trial primary completion date • Esophageal Cancer • Gastric Cancer • Gastroesophageal Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor

An Exploratory Study on the Treatment of Anaplastic Thyroid Carcinoma with Camrelizumab Combined with Apatinib and Capecitabine (ChiCTR) - P2 | N=20 | Completed | Sponsor: Sichuan Cancer Hospital; Sichuan Cancer Hospital

New P2 trial • Oncology • Solid Tumor • Thyroid Gland Anaplastic Carcinoma • Thyroid Gland Carcinoma • BRAF • PD-L1

Clinical study of Carrilizumab combined with Apatinib in prevention of postoperative recurrence of early hepatocellular carcinoma (ChiCTR) - P=N/A | N=55 | Not yet recruiting | Sponsor: Medical Institution; Medical Institution

New trial • Hepatocellular Cancer • Oncology • Solid Tumor

A Phase II Trial of Organoid Drug Sensitivity Testing to Guide Therapy in Unresectable Hepatocellular Carcinoma (clinicaltrials.gov) - P2 | N=94 | Not yet recruiting | Sponsor: Eastern Hepatobiliary Surgery Hospital

New P2 trial • Hepatocellular Cancer • Oncology • Solid Tumor

An Exploratory Clinical Study of Adebrelimab Combined with Apatinib and Chemotherapy as Neoadjuvant Therapy for Initially Unresectable Stage III Non-Small Cell Lung Cancer (ChiCTR) - P=N/A | N=52 | Not yet recruiting | Sponsor: Harbin Medical University Cancer Hospital; Harbin Medical University Cancer Hospital

New trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

A Study of Apatinib + Lenvatinib Conversion Followed by Surgical Resection for Unresectable Advanced HCC: A Prospective, Single-Arm, Historical Control, IIT Study (ChiCTR) - P=N/A | N=73 | Not yet recruiting | Sponsor: Affiliated hangzhou first people's hospital, zhejiang university school of medicine; Affiliated hangzhou first people's hospital, zhejiang university

New trial • Hepatocellular Cancer • Oncology • Solid Tumor

Case report: Immune checkpoint inhibitor-induced fulminant diabetic ketoacidosis: a case-based review and considerations for immunotherapy discontinuation. (PubMed, Front Immunol) - "An elderly male diagnosed with Stage IV LUAD achieved sustained stable disease (SD) and symptomatic improvement through a sequential therapeutic strategy, including platinum-based chemotherapy followed by the PD-1 inhibitor sintilimab combined with anti-angiogenic agents (apatinib or anlotinib). This case demonstrates that while ICIs can provide exceptional long-term benefits in advanced NSCLC, particularly in patients with highly immunogenic mutation profiles, they may also trigger late-onset fatal irAEs. Our findings underscore the imperative for close, long-term metabolic surveillance throughout the course of immunotherapy, regardless of treatment duration or radiological stability."

Checkpoint inhibition • IO biomarker • Journal • Review • Diabetes • Endocrine Cancer • Lung Adenocarcinoma • Lung Cancer • Metabolic Disorders • Non Small Cell Lung Cancer • Oncology • Solid Tumor • KRAS • TP53

The efficacy and safety of immunoradiotherapy plus gemcitabine, apatinib, and PD-L1 monoclonal antibody as first-line treatment for unresectable biliary tract tumors. (ChiCTR) - P=N/A | N=33 | Completed | Sponsor: Nanjing Drum Tower Hospital; Nanjing Drum Tower Hospital

New trial • Biliary Cancer • Biliary Tract Cancer • Cholangiocarcinoma • Gallbladder Cancer

A Phase II Study of PD-1 Monoclonal Antibody Combined with Apatinib, With or Without Chemotherapy, as Maintenance Therapy for Patients with Advanced Driver Gene-Negative NSCLC Who Have Not Progressed (ChiCTR) - P2 | N=86 | Not yet recruiting | Sponsor: Cancer Hospital Chinese Academy of Medical Sciences; Cancer Hospital Chinese Academy of Medical Sciences

New P2 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK

A Single-Arm, Prospective Clinical Study of SBRT Sequential Aidebelimab Combined with Apatinib as Neoadjuvant Therapy for Resectable Non-Small Cell Lung Cancer (ChiCTR) - P2 | N=29 | Not yet recruiting | Sponsor: Xiamen Hospital of Zhongshan Hospital Affiliated to Fudan Un; Xiamen Hospital of Zhongshan Hospital Affiliated to Fudan Un

New P2 trial • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1

A Prospective, Single-arm, Exploratory Study of Trifluridine/Tipiracil (TAS-102) Combined With Apatinib as Third-line Therapy for Advanced Gastric Cancer (clinicaltrials.gov) - P=N/A | N=30 | Not yet recruiting | Sponsor: Anhui Provincial Cancer Hospital

New trial • Gastric Cancer • Oncology • Solid Tumor

Exploration of Treatment Strategies After Concurrent Chemoradiotherapy for LS-SCLC Guided by MRD (clinicaltrials.gov) - P2 | N=44 | Not yet recruiting | Sponsor: Peking University Cancer Hospital & Institute

New P2 trial • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor